Chemistry:BK-5Cl-NM-AMT
BK-5Cl-NM-AMT, or βk-5Cl-NM-αMT, also known as β-keto-5-chloro-N-methyl-αMT or α,N-dimethyl-5-chloro-β-ketotryptamine, is a monoamine releasing agent of the tryptamine, α-alkyltryptamine, and β-ketotryptamine families.[1]
It is known to induce the release of serotonin and dopamine, with respective EC50 values of 200 nM and 865 nM in rat brain synaptosomes, whereas norepinephrine release was not reported.[1] In contrast to many other tryptamines, the drug is inactive as an agonist of serotonin receptors including the 5-HT1, 5-HT2, and 5-HT3 receptors.[1] In addition, unlike other α-alkyltryptamines like α-methyltryptamine (αMT), it is inactive as a monoamine oxidase inhibitor (MAOI).[1]
BK-5Cl-NM-AMT was first described in the literature by 2023.[1] It was patented by Matthew Baggott and Tactogen as a potential novel entactogen.[1] BK-5Cl-NM-AMT is the 5-chloro derivative of BK-NM-AMT.[1][2][3][4] Other analogues of the drug include BK-5F-NM-AMT and BK-5Br-NM-AMT.[1]
See also
- 5-Chloro-AMT
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 Baggott MJ, "Advantageous tryptamine compositions for mental disorders or enhancement", WO patent 2022061242, published 2023 March 24, assigned to Tactogen
- ↑ Yadav BJ (16 July 2019). Understanding Structure–Activity Relationship of Synthetic Cathinones (Bath Salts) Utilizing Methylphenidate. Theses and Dissertations (Doctor of Philosophy thesis). Virginia Commonwealth University. p. 40. doi:10.25772/MJQW-8C64. Retrieved 24 November 2024 – via VCU Scholars Compass.
- ↑ "The dopamine, serotonin and norepinephrine releasing activities of a series of methcathinone analogs in male rat brain synaptosomes". Psychopharmacology (Berl) 236 (3): 915–924. March 2019. doi:10.1007/s00213-018-5063-9. PMID 30341459.
- ↑ Baggott MJ, Dalziel S, "Specialized combinations for mental disorders or mental enhancement", US patent 20240335414, published 10 October 2024
External links
 |  |
